ASH News Daily 2012 - Saturday, December 8, 2012 - (Page B-5)

Saturday, December 8, 2012 ASH NewS DAily Page B–5 ® Hematology in Cyberspace: Benefiting From New Technologies and Social Networking Plan to Attend Tonight’s ASH Practice Forum and Reception T his year’s Practice Forum will provide clinicians with a greater understanding of the existing and emerging technologies that help improve patient care and practice efficiency as well as provide opportunities for additional education and collaboration. Technology supporting health care is evolving at a rapid pace and can provide many advantages when appropriately utilized. Despite this, many practice-based hematologists remain reluctant to adopt health information technology (HIT). Even the most enthusiastic users are often records and move toward additional technology-related programs. This will be followed by an overview of emerging trends in HIT by Richard P. Mansour, MD, chief medical informatics officer of AllScripts. Dr. Mansour will discuss new “cyberspace tools” that are available to access clinically relevant diagnostic, therapeutic, and practice management information and how these technologies are applicable to the practice of hematology. Next, Mark Sitarik, MD, medical director of ASH Practice Forum 6:00 - 7:30 p.m. Omni Hotel at CNN Center, International Ballroom D Medical Informatics at McKesson Specialty Health and a hematologistoncologist at the Rocky Mountain Cancer Centers in Boulder, CO, will provide examples of how he successfully implemented new HIT tools into his practice, the advantages and disadvantages of these technologies, and the best uses and application in a hematology practice. Drs. Mansour and Sitarik will also provide their perspectives on social networking in the medical profession and its potential role for increased education, communication, and collaboration among hematologists. The session will conclude with a question-andanswer period. REGULATE REDUCE JAK signaling JAK2 Bo Vis ot it u h s #3 at 72 3 splenomegaly and symptoms of MF* overwhelmed by the pace of change and have difficulty keeping up with new developments. Join your colleagues to learn how to navigate through the evolving world of useful cyberspace resources and products. The session will begin with a discussion about the latest federal legislative and regulatory highlights by Mila Becker, Esq., senior director of ASH’s Government Relations, Practice, and Scientific Affairs Department, and Ellen Riker, government relations consultant from Cavarocchi, Ruscio, Dennis Associates in Washington, DC. Ms. Becker and Ms. Riker will focus on federal efforts to encourage the adoption of electronic medical JAK1 Jaka ®—superior reductions in spleen volume and improvements in symptom scores at Week 241,2,a,b Jaka Signi cantly more patients receiving Jaka vs placebo had – A ≥35% reduction in spleen volume (41.9% vs 0.7%, respectively; P < 0.0001)1,2,a – A ≥50% improvement in Total Symptom Score (TSS) (45.9% vs 5.3%, respectively; P < 0.0001)1,2,a,b • At baseline, mean TSS was 18.0 in the Jakafi group and 16.5 in the placebo group Reductions in spleen volume and improvements in TSS were seen with Jaka in both JAK2 V617F-positive and JAK2 V617F-negative patients, relative to placebo2 Visit www.jaka .com/ASH for more information on Jaka and MF plus valuable educational resources. , *Intermediate or high-risk myelo brosis (MF). A special reception for practitioners will follow the Practice Forum, from 7:30 to 8:30 p.m. in the Omni Hotel at CNN Center, International Ballroom A-B. This reception provides an opportunity for participants to network and talk directly with members of the ASH Committee on Practice to express issues of concern, learn more about the Society’s practice-related initiatives, and share personal experiences. Beverages and hors d’oeuvres will be provided. Indications and Usage Jaka is indicated for treatment of patients with intermediate or high-risk myelo brosis, including primary myelo brosis, post–polycythemia vera myelo brosis and post–essential thrombocythemia myelo brosis. Important Safety Information • Treatment with Jakafi can cause hematologic adverse reactions, including thrombocytopenia, anemia and neutropenia, which are each doserelated effects, with the most frequent being thrombocytopenia and anemia. A complete blood count must be performed before initiating therapy with Jaka . Complete blood counts should be monitored as clinically indicated and dosing adjusted as required • The three most frequent non-hematologic adverse reactions were bruising, dizziness and headache a • Patients with platelet counts <200 × 109/L at patients receiving Jaka for signs and symptoms of infection (including herpes zoster) and initiate the start of therapy are more likely to develop appropriate treatment promptly thrombocytopenia during treatment. Thrombocytopenia was generally reversible and • A dose modification is recommended when was usually managed by reducing the dose or administering Jakafi with strong CYP3A4 inhibitors temporarily withholding Jaka . If clinically indicated, or in patients with renal or hepatic impairment platelet transfusions may be administered [see Dosage and Administration]. Patients should be closely monitored and the dose titrated based • Patients developing anemia may require blood on safety and ef cacy transfusions. Dose modi cations of Jaka for patients developing anemia may also be considered • There are no adequate and well-controlled studies of Jaka in pregnant women. Use of Jaka during • Neutropenia (ANC <0.5 × 109/L) was generally pregnancy is not recommended and should only be reversible and was managed by temporarily used if the potential bene t justi es the potential withholding Jaka risk to the fetus • Patients should be assessed for the risk of • Women taking Jakafi should not breast-feed. developing serious bacterial, mycobacterial, Discontinue nursing or discontinue the drug, fungal and viral infections. Active serious taking into account the importance of the drug infections should have resolved before starting to the mother Jakafi. Physicians should carefully observe As studied in COMFORT-I, a randomized, double-blind, placebo-controlled phase III study with 309 total patients (United States, Canada, Australia). The primary endpoint was the proportion of subjects achieving a ≥35% reduction in spleen volume from baseline to Week 24 as measured by magnetic resonance imaging (MRI) or computed tomography (CT) . A secondary endpoint was the proportion of subjects with a ≥50% reduction in TSS from baseline to Week 24 as measured by the daily patient diary, the modi ed Myelo brosis Symptom Assessment Form (MFSAF v2.0).1,2 b Symptom scores were captured by a daily patient diary recorded for 25 weeks. TSS encompasses debilitating symptoms of MF, including abdominal discomfort, early satiety, pain under left ribs, pruritus, night sweats and bone/muscle pain. Symptom scores ranged from 0 to 10 with 0 representing symptoms “absent” and 10 representing “worst imaginable” symptoms. These scores were added to create the daily total score, which has a maximum of 60.1,2 References: 1. Jaka Prescribing Information. Incyte Corporation. June 2012. 2. Verstovsek S, Mesa RA, Gotlib J, et al. N Engl J Med. 2012;366:799-807. Please see Brief Summary of Full Prescribing Information on the following page. Jaka is a registered trademark of Incyte Corporation. © 2012, Incyte Corporation. All rights reserved. RUX-1160E 10/12 

Table of Contents for the Digital Edition of ASH News Daily 2012 - Saturday, December 8, 2012

ASH News Daily 2012 - Saturday, December 8, 2012

https://www.nxtbookmedia.com